Stocks mostly rose on Thursday after jobless claims fell to a three-month low.» Read More
NEW YORK, Nov 22- U.S. stocks were little changed on Friday amid a dearth of data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials broke 16,000 for the first time.
Nov 18- AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. AbbVie shares rose 3 percent. Shares of Enanta Pharmaceuticals Inc, which collaborates with AbbVie on one of the drugs included in the treatment, rose 4 percent.
Health-care stocks are surging amid the confusion of Obamacare. Apparently, investors don't see the current morass as problematic at all.
"You still have to be in a group that continues to grow whether the economy's growing or not growing," Stephen Weiss of Short Hills Capital says.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Some of the names on the move ahead of the open.
Check out which companies are making headlines after the bell Tuesday:
Oct 29- Vertex Pharmaceuticals Inc lowered its full-year revenue forecast and said it would cut about 15 percent of its workforce after sales of its hepatitis C drug plunged in the third quarter. The company's hepatitis C treatment, Incivek, was hugely popular when it was launched in May 2011 and revenue from the drug topped $1 billion in a few months.
Cramer’s noticed a theme in the market. Certain earnings have included gigantic upside surprises.
WASHINGTON, Oct 25- A federal advisory panel recommended on Friday that the U.S. Food and Drug Administration approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir, paving the way for a treatment that is more effective than current therapies and takes less time.
WASHINGTON, Oct 25- A federal advisory panel recommended on Friday that U.S. health regulators approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir, paving the way for a treatment that is more effective and shorter in duration than current therapies. The FDA is not bound to follow the advice of its panels but typically does so.
WASHINGTON, Oct 25- A federal advisory panel recommended on Friday that U.S. health regulators approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir.
LONDON, Oct 25- European regulators have recommended approval of Swiss firm Actelion's new pulmonary arterial hypertension drug Opsumit and a novel antidepressant called Brintellix from Denmark's Lundbeck.
Talking Squawk looks at Kid Rock calling out Madonna on Detroit, Carl Icahn's Apple obsession and some Greenspeak.
Take a look at some of Wednesday's midday movers:
Oct 23- Gilead Sciences Inc's sofosbuvir drug is safe and effective when used in combination with other therapies to treat hepatitis C, according to reviewers with the U.S. Food and Drug Administration.
Oct 23- Gilead Sciences Inc's drug sofosbuvir is safe and effective when used in combination with other therapies to treat hepatitis C, according to reviewers with the U.S. Food and Drug Administration.
Oct 22- A new hepatitis C drug made by Johnson& Johnson showed an acceptable safety profile in clinical trials, reviewers for the U.S. Food and Drug Administration said on Tuesday. J&J shares were up nearly 1 percent to $92 in morning trade on the New York Stock Exchange.
"We're going to be cruising along into the afternoon," Jon Najarian says.
The "Fast Money" traders share their final trades of the day.